Scholar Rock (SRRK) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $5.72B and a free-cash-flow yield of -5.6%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 2.5/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Rising · +46.5% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-24.0%
How far the last close sits under the highest price of the past five years.
Market cap
$5.72B
Trailing P/E
—
Price / book
22.5
Price / sales
—
FCF yield
-5.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
-100.0%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.6
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
SRRK earnings
Next report: Nov 10, 2026 (Q3 2026, EPS estimate -$0.84).
Beat the EPS estimate in 0 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q2 2026
Aug 6, 2026
-$0.84
-$0.84
+0.0%
$0
Q1 2026
May 7, 2026
-$0.83
-$0.78
-6.4%
$0
Q4 2025
Mar 3, 2026
-$0.88
-$0.88
+0.0%
$0
Q3 2025
Nov 14, 2025
-$0.90
-$0.84
-7.1%
$0
SRRK analyst price target
Median target $71.50 from 16 analysts, ranging $58.00 – $84.00.
Nama's AI scorecard currently rates Scholar Rock Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SRRK report earnings?
Scholar Rock's next scheduled report is on Nov 10, 2026. Analysts expect EPS of -$0.84.
What is the SRRK price target?
The median analyst price target from 16 analysts is $71.50, with a range of $58.00 – $84.00.
Is SRRK Shariah compliant?
Nama's AAOIFI-style screen reads Scholar Rock as Can't Tell. A figure the screen needs is missing, so it can't tell.